$EMMA
Emmaus Life Sciences, Inc. Stock $emma

$emma Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024080918 Filed on July 03, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.506M	$7.067M	$29.60M
YoY Change	-62.89%	19.17%	60.94%
Cost Of Revenue	$257.0K	$191.0K	$1.342M
YoY Change	-40.09%	-70.39%	-48.15%
Gross Profit	$2.249M	$6.876M	$28.26M
YoY Change	-64.44%	30.1%	78.81%
Gross Profit Margin	89.74%	97.3%	95.47%
Selling, General & Admin	$4.806M	$5.355M	$23.53M
YoY Change	-33.25%	-13.27%	13.86%
% of Gross Profit	213.69%	77.88%	83.26%
Research & Development	$183.0K	$166.0K	$1.189M
YoY Change	-36.68%	-68.62%	-31.07%
% of Gross Profit	8.14%	2.41%	4.21%
Depreciation & Amortization	$6.000K	$2.000K	$32.00K
YoY Change	-33.33%	-84.62%	-39.62%
% of Gross Profit	0.27%	0.03%	0.11%
Operating Expenses	$4.989M	$5.521M	$24.72M
YoY Change	-33.38%	-17.63%	10.39%
Operating Profit	-$2.740M	$1.355M	$3.540M
YoY Change	135.19%	-195.56%	-153.75%
Interest Expense	$1.910M	-$251.0K	$7.383M
YoY Change	27.16%	-116.05%	47.28%
% of Operating Profit		-18.52%	208.56%
Other Income/Expense, Net	$147.0K	$167.0K	$681.0K
YoY Change	-8.13%	11.33%	0.15%
Pretax Income	-$4.355M	$1.097M	-$3.792M
YoY Change	25.22%	407.87%	-64.11%
Income Tax	-$7.000K	-$112.0K	-$59.00K
% Of Pretax Income		-10.21%
Net Earnings	-$4.348M	$1.209M	-$3.700M
YoY Change	24.23%	504.5%	-65.09%
Net Earnings / Revenue	-173.5%	17.11%	-12.5%
Basic Earnings Per Share	-$0.07		-$0.07
Diluted Earnings Per Share	-$0.07	$0.02	-$0.07
COMMON SHARES
Basic Shares Outstanding	61.85M	53.64M	53.11M
Diluted Shares Outstanding	61.85M		53.11M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.712M	$2.547M	$2.547M
YoY Change	-3.49%	26.03%	26.03%
Cash & Equivalents	$1.712M	$2.547M
Short-Term Investments
Other Short-Term Assets	$762.0K	$596.0K	$1.727M
YoY Change	90.02%	32.74%	14.07%
Inventory	$1.527M	$1.711M	$1.711M
Prepaid Expenses	$442.0K	$536.0K
Receivables	$2.990M	$5.524M	$5.524M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.844M	$11.51M	$11.51M
YoY Change	5.74%	83.0%	83.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.00K	$59.00K	$2.396M
YoY Change	-20.83%	-21.33%	-16.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$19.25M	$20.98M	$20.98M
YoY Change	0.75%	11.42%	-45.93%
Other Assets	$310.0K	$296.0K	$296.0K
YoY Change	11.91%	12.55%	12.55%
Total Long-Term Assets	$21.70M	$23.67M	$23.67M
YoY Change	-47.75%	-43.56%	-43.56%
TOTAL ASSETS
Total Short-Term Assets	$7.844M	$11.51M	$11.51M
Total Long-Term Assets	$21.70M	$23.67M	$23.67M
Total Assets	$29.54M	$35.18M	$35.18M
YoY Change	-39.64%	-27.05%	-27.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.565M	$5.887M	$5.887M
YoY Change	38.71%	55.54%	55.54%
Accrued Expenses	$8.519M	$8.174M	$12.70M
YoY Change	26.81%	12.92%	21.36%
Deferred Revenue
YoY Change
Short-Term Debt	$4.132M	$3.573M	$3.573M
YoY Change	-26.75%	-36.37%	-36.37%
Long-Term Debt Due	$24.31M	$24.60M	$24.60M
YoY Change	5.63%	14.57%	14.57%
Total Short-Term Liabilities	$62.43M	$61.51M	$61.51M
YoY Change	7.9%	13.22%	13.22%
LONG-TERM LIABILITIES
Long-Term Debt	$2.231M	$2.226M	$2.226M
YoY Change	-49.59%	-40.26%	-40.26%
Other Long-Term Liabilities	$16.97M	$17.36M	$19.20M
YoY Change	-16.24%	-20.04%	-20.87%
Total Long-Term Liabilities	$16.97M	$17.36M	$21.43M
YoY Change	-16.24%	-20.04%	-23.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.43M	$61.51M	$61.51M
Total Long-Term Liabilities	$16.97M	$17.36M	$21.43M
Total Liabilities	$83.19M	$82.94M	$82.94M
YoY Change	-2.02%	0.75%	0.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$260.5M	-$256.1M
YoY Change	1.78%	1.49%
Common Stock	$225.6M	$225.4M
YoY Change	1.18%	2.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$53.64M	-$47.76M	-$47.76M
YoY Change
Total Liabilities & Shareholders Equity	$29.54M	$35.18M	$35.18M
YoY Change	-39.64%	-27.05%	-27.05%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.348M	$1.209M	-$3.700M
YoY Change	24.23%	504.5%	-65.09%
Depreciation, Depletion And Amortization	$6.000K	$2.000K	$32.00K
YoY Change	-33.33%	-84.62%	-39.62%
Cash From Operating Activities	$140.0K	$1.037M	-$1.503M
YoY Change	-110.84%	-38.16%	-70.37%
INVESTING ACTIVITIES
Capital Expenditures	$4.000K	$7.000K	$17.00K
YoY Change	-33.33%	-12.5%	-34.62%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$5.000K	-$415.0K
YoY Change	-100.0%	-100.47%	-82.42%
Cash From Investing Activities	-$4.000K	-$2.000K	-$432.0K
YoY Change	-99.63%	-99.81%	-81.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-955.0K	-3.000K	2.477M
YoY Change	-144.61%	-101.76%	-65.75%
NET CHANGE
Cash From Operating Activities	140.0K	1.037M	-1.503M
Cash From Investing Activities	-4.000K	-2.000K	-432.0K
Cash From Financing Activities	-955.0K	-3.000K	2.477M
Net Change In Cash	-835.0K	1.032M	526.0K
YoY Change	238.06%	31.46%	-303.88%
FREE CASH FLOW
Cash From Operating Activities	$140.0K	$1.037M	-$1.503M
Capital Expenditures	$4.000K	$7.000K	$17.00K
Free Cash Flow	$136.0K	$1.030M	-$1.520M
YoY Change	-110.48%	-38.29%	-70.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000822370
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList	http://www.emmausmedical.com/20231231#GainLossOnInvestmentInConvertibleBond
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList	http://www.emmausmedical.com/20231231#GainLossOnInvestmentInConvertibleBond
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Other Comprehensive Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Other Comprehensive Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35527
CY2023	dei	Entity Registrant Name EntityRegistrantName	Emmaus Life Sciences, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0419387
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	21250 Hawthorne Boulevard
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Torrance
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90503
CY2023	dei	City Area Code CityAreaCode	310
CY2023	dei	Local Phone Number LocalPhoneNumber	214‑0065
CY2023	dei	Security12g Title Security12gTitle	Common stock, par value $0.001 per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8857638
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61845963
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	BAKER TILLY US, LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2547000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2021000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5524000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	375000
CY2023Q4	us-gaap	Inventory Net InventoryNet	1711000
CY2022Q4	us-gaap	Inventory Net InventoryNet	2379000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1727000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1514000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11509000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6289000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75000
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	18828000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2337000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2799000
CY2023Q4	emma	Investment In Convertible Bond InvestmentInConvertibleBond	20978000
CY2022Q4	emma	Investment In Convertible Bond InvestmentInConvertibleBond	19971000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	296000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	263000
CY2023Q4	us-gaap	Assets Assets	35179000
CY2022Q4	us-gaap	Assets Assets	48225000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17725000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13549000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	703000
CY2023Q4	emma	Conversion Feature Derivative Note Payable ConversionFeatureDerivativeNotePayable	451000
CY2022Q4	emma	Conversion Feature Derivative Note Payable ConversionFeatureDerivativeNotePayable	3248000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14681000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12917000
CY2023Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	65000
CY2022Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	70000
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	16383000
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	14655000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	61507000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54323000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1839000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2553000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17363000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21714000
CY2023Q4	us-gaap	Liabilities Liabilities	82935000
CY2022Q4	us-gaap	Liabilities Liabilities	82316000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61845963
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61845963
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49583501
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49583501
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	62000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	50000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	225333000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	220815000
CY2023Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	16869000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-160000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2619000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256122000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252337000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-47756000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-34091000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35179000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48225000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29597000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18390000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1342000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	2588000
CY2023	us-gaap	Gross Profit GrossProfit	28255000
CY2022	us-gaap	Gross Profit GrossProfit	15802000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1189000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1725000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8635000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7493000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14891000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13170000
CY2023	us-gaap	Operating Expenses OperatingExpenses	24715000
CY2022	us-gaap	Operating Expenses OperatingExpenses	22388000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	3540000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6586000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-821000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-501000
CY2023	emma	Gain Loss On Warrant Derivative Liabilities GainLossOnWarrantDerivativeLiabilities	1195000
CY2022	emma	Gain Loss On Warrant Derivative Liabilities GainLossOnWarrantDerivativeLiabilities	1304000
CY2023	emma	Gain Loss On Conversion Feature Derivative Note Payable GainLossOnConversionFeatureDerivativeNotePayable	2773000
CY2022	emma	Gain Loss On Conversion Feature Derivative Note Payable GainLossOnConversionFeatureDerivativeNotePayable	4259000
CY2023	emma	Gain Loss On Investment In Convertible Bond GainLossOnInvestmentInConvertibleBond	-297000
CY2022	emma	Gain Loss On Investment In Convertible Bond GainLossOnInvestmentInConvertibleBond	-133000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1713000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1913000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1767000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2662000
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	681000
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	680000
CY2023	us-gaap	Interest Expense InterestExpense	7383000
CY2022	us-gaap	Interest Expense InterestExpense	5013000
CY2023	emma	Nonoperating Income Expense Including Income Loss From Equity Method Investments NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments	-7332000
CY2022	emma	Nonoperating Income Expense Including Income Loss From Equity Method Investments NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments	-3979000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3792000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10565000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-59000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3733000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10625000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3033000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3084000
CY2023	emma	Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss	403000
CY2022	emma	Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss	7000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-977000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	713000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2459000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2364000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1274000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12989000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53105388
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53105388
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49439867
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49439867
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-21450000
CY2022	emma	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	213000
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	119000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3084000
CY2022	emma	Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss	7000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	713000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10625000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-34091000
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4071000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	407000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3033000
CY2023	emma	Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss	403000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-977000
CY2023	emma	Loan Receivable From Affiliates LoanReceivableFromAffiliates	16869000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3733000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-47756000
CY2023	us-gaap	Profit Loss ProfitLoss	-3733000
CY2022	us-gaap	Profit Loss ProfitLoss	-10625000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000
CY2023	emma	Inventory Reserve InventoryReserve	-12000
CY2022	emma	Inventory Reserve InventoryReserve	-1565000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2568000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1815000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1911000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2773000
CY2023	emma	Tax Benefit Recognized On Unrealized Gain On Debt Securities TaxBenefitRecognizedOnUnrealizedGainOnDebtSecurities	100000
CY2023	emma	Gain Loss On Investment In Convertible Bond GainLossOnInvestmentInConvertibleBond	-297000
CY2022	emma	Gain Loss On Investment In Convertible Bond GainLossOnInvestmentInConvertibleBond	-133000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1713000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1913000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-821000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-501000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000
CY2022	emma	Gain Loss On Sale Of Loss On Leased Assets GainLossOnSaleOfLossOnLeasedAssets	-22000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1262000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16000
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	119000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	334000
CY2023	emma	Gain Loss On Warrant Derivative Liabilities GainLossOnWarrantDerivativeLiabilities	1195000
CY2022	emma	Gain Loss On Warrant Derivative Liabilities GainLossOnWarrantDerivativeLiabilities	1304000
CY2023	emma	Gain Loss On Conversion Feature Derivative Note Payable GainLossOnConversionFeatureDerivativeNotePayable	2773000
CY2022	emma	Gain Loss On Conversion Feature Derivative Note Payable GainLossOnConversionFeatureDerivativeNotePayable	4259000
CY2023	emma	Gain Loss On Embedded Derivative Note Payable From Related Party GainLossOnEmbeddedDerivativeNotePayableFromRelatedParty	36000
CY2022	emma	Gain Loss On Embedded Derivative Note Payable From Related Party GainLossOnEmbeddedDerivativeNotePayableFromRelatedParty	6000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5149000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-607000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-650000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-434000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	214000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-239000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-591000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4800000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3678000
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2025000
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2777000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-918000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-317000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1503000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5073000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2232000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2919000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000
CY2023	emma	Loan To Equity Method Investee LoanToEquityMethodInvestee	-2647000
CY2022	emma	Loan To Equity Method Investee LoanToEquityMethodInvestee	-5280000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-432000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2387000
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	7050000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6468000
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	927000
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3900000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1000000
CY2023	emma	Proceeds From Related Party Convertible Debt ProceedsFromRelatedPartyConvertibleDebt	1000000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7390000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1809000
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	110000
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	976000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	350000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2477000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7233000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-16000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-31000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	526000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-258000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2021000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2279000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2547000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2021000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2453000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1335000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	83000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000
CY2023	emma	Capitalized Interest On Renewal Of Notes Payable CapitalizedInterestOnRenewalOfNotesPayable	618000
CY2023	us-gaap	Notes Issued1 NotesIssued1	3590000
CY2023	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	189000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTE 1—DESCRIPTION OF BUSINESS</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">References herein to the “Company” or “Emmaus” means Emmaus Life Sciences, Inc. and its direct and indirect subsidiaries.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nature of Business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The Company is a commercial-stage biopharmaceutical company engaged in the marketing and sales of the Company’s lead product Endari® (prescription grade L-glutamine oral powder), which is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older. Endari® has received Orphan Drug designation from the FDA which designation generally affords marketing exclusivity for Endari® in the U.S. for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period ending in July 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Endari® is marketed and sold by the internal commercial sales team. Endari® is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari® for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari® is also reimbursable by many commercial payors. The Company has agreements in place with the nation’s leading distributors, as well as physician group purchasing organizations and pharmacy benefits managers, making Endari® available at selected retail and specialty pharmacies nationwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700000
CY2023Q4	emma	Working Capital Deficit WorkingCapitalDeficit	50000000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—Financial statements prepared in accordance with GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include those relating to revenue recognition on product sales, the estimated useful lives of equipment, impairment of assets, inventory reserve, allowance for credit losses, implied interest rate used on operating leases, the variables used to calculate the valuation of investment in convertible bond, conversion features, stock options and warrants, and estimated accruals on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates under different assumptions or conditions. To the extent there are material differences between these estimates and actual results, the Company’s financial statements will be affected.</span></p>
CY2023Q4	emma	Valuation Allowance Accounts Receivable ValuationAllowanceAccountsReceivable	124000
CY2022Q4	emma	Valuation Allowance Accounts Receivable ValuationAllowanceAccountsReceivable	0
CY2023	emma	Number Of Vendors NumberOfVendors	1
CY2022	emma	Number Of Vendors NumberOfVendors	1
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5000000
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	124525180
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	52338872
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29597000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18390000
CY2021Q4	emma	Revenue Allowance And Accrual Activities RevenueAllowanceAndAccrualActivities	5153000
CY2022	emma	Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear	6945000
CY2022	emma	Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales	-499000
CY2022	emma	Revenue Allowance And Accrual Activities Credit And Payments Made RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade	7106000
CY2022Q4	emma	Revenue Allowance And Accrual Activities RevenueAllowanceAndAccrualActivities	5491000
CY2023	emma	Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear	8219000
CY2023	emma	Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales	-32000
CY2023	emma	Revenue Allowance And Accrual Activities Credit And Payments Made RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade	6009000
CY2023Q4	emma	Revenue Allowance And Accrual Activities RevenueAllowanceAndAccrualActivities	7733000
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1329000
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1393000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	186000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	513000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5163000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5428000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4967000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4955000
CY2023Q4	us-gaap	Inventory Net InventoryNet	1711000
CY2022Q4	us-gaap	Inventory Net InventoryNet	2379000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	595000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	598000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	536000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	467000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	596000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	449000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1727000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1514000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	521000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	505000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	430000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75000
CY2023	us-gaap	Depreciation Depreciation	32000
CY2022	us-gaap	Depreciation Depreciation	39000
CY2020Q3	us-gaap	Debt Instrument Call Date Earliest DebtInstrumentCallDateEarliest	2020-09-28
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-126000
CY2022Q1	us-gaap	Other Income OtherIncome	41000
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	106000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	19971000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	26100000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	-2232000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	-2919000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	106000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-126000
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	3133000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-3084000
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20978000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	19971000
CY2023Q4	emma	Clinical And Regulatory Expenses ClinicalAndRegulatoryExpenses	696000
CY2022Q4	emma	Clinical And Regulatory Expenses ClinicalAndRegulatoryExpenses	361000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	721000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	626000
CY2023Q4	emma	Accrued Selling Expenses AccruedSellingExpenses	1498000
CY2022Q4	emma	Accrued Selling Expenses AccruedSellingExpenses	1363000
CY2023Q4	emma	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	914000
CY2022Q4	emma	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	650000
CY2023Q4	emma	Accruednonemployeeboardmembercompensation Accruednonemployeeboardmembercompensation	766000
CY2022Q4	emma	Accruednonemployeeboardmembercompensation Accruednonemployeeboardmembercompensation	484000
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1292000
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	301000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5887000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3785000
CY2023Q4	emma	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	542000
CY2022Q4	emma	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	144000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3122000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2381000
CY2023Q4	emma	Accrued Payroll Salary And Taxes Current AccruedPayrollSalaryAndTaxesCurrent	1270000
CY2022Q4	emma	Accrued Payroll Salary And Taxes Current AccruedPayrollSalaryAndTaxesCurrent	1263000
CY2023Q4	emma	Accrued Government Rebates And Other Rebates Current AccruedGovernmentRebatesAndOtherRebatesCurrent	5881000
CY2022Q4	emma	Accrued Government Rebates And Other Rebates Current AccruedGovernmentRebatesAndOtherRebatesCurrent	5536000
CY2023Q4	emma	Accured Due To Customer Current AccuredDueToCustomerCurrent	844000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	179000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	440000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8174000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7239000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17725000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13549000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14681000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12917000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17363000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21714000
CY2023Q4	emma	Debt Instrument Principal Outstanding Amount DebtInstrumentPrincipalOutstandingAmount	30563000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	617000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	29946000
CY2023	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	116906234
CY2022Q4	emma	Debt Instrument Principal Outstanding Amount DebtInstrumentPrincipalOutstandingAmount	30418000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2918000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	27562000
CY2022	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	41644749
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.12
CY2022Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.08
CY2023Q4	emma	Debt Weighted Average Effective Interest Rate DebtWeightedAverageEffectiveInterestRate	0.23
CY2022Q4	emma	Debt Weighted Average Effective Interest Rate DebtWeightedAverageEffectiveInterestRate	0.20
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	28242000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2321000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	30563000
CY2022Q3	emma	Debt Instrument Principle Payments DebtInstrumentPrinciplePayments	1600000
CY2022Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	32000
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	84000
CY2022Q3	emma	Warrants Granted Term WarrantsGrantedTerm	P5Y
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	500000
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.5
CY2023Q1	emma	Warrants Granted Term WarrantsGrantedTerm	P5Y
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7500000
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.5
CY2023	emma	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1200000
CY2023	emma	Summary Of Assumptions Used To Value Warrants SummaryOfAssumptionsUsedToValueWarrants	<p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the assumptions used to value the warrants:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.448%;"></td> <td style="width:2.519%;"></td> <td style="width:1%;"></td> <td style="width:16.256999999999998%;"></td> <td style="width:1%;"></td> <td style="width:2.02%;"></td> <td style="width:17.756%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">January 2023</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock price</span></p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.10</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.31</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.49</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price</span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.50</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.47</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> - $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.50</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term</span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.03</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.24</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free rate</span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.92</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.53</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.66</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td> <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129.40</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130.23</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116.40</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119.14</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-94000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	30000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	35000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	30000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-59000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17564000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17978000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	12085000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	11837000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6792000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6149000
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	37000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	310000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	380000
CY2023Q4	emma	Deferred Tax Assets Unearned Revenue DeferredTaxAssetsUnearnedRevenue	2603000
CY2022Q4	emma	Deferred Tax Assets Unearned Revenue DeferredTaxAssetsUnearnedRevenue	2472000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	545000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	442000
CY2023Q4	emma	Deferred Tax Assets Unrealized Gain Loss On Foreign Exchange Translation And Other DeferredTaxAssetsUnrealizedGainLossOnForeignExchangeTranslationAndOther	1295000
CY2022Q4	emma	Deferred Tax Assets Unrealized Gain Loss On Foreign Exchange Translation And Other DeferredTaxAssetsUnrealizedGainLossOnForeignExchangeTranslationAndOther	789000
CY2023Q4	emma	Deferred Tax Assets Section One Seventy Four Expenditures DeferredTaxAssetsSectionOneSeventyFourExpenditures	420000
CY2022Q4	emma	Deferred Tax Assets Section One Seventy Four Expenditures DeferredTaxAssetsSectionOneSeventyFourExpenditures	292000
CY2023Q4	emma	Deferred Tax Assets Unrealized Gain Loss On Long Term Investment DeferredTaxAssetsUnrealizedGainLossOnLongTermInvestment	30000
CY2022Q4	emma	Deferred Tax Assets Unrealized Gain Loss On Long Term Investment DeferredTaxAssetsUnrealizedGainLossOnLongTermInvestment	33000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1678000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4130000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43322000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44539000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42895000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44112000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	427000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	427000
CY2023Q4	emma	Deferred Tax Liabilities Unrealized Loss On Trading Securities DeferredTaxLiabilitiesUnrealizedLossOnTradingSecurities	427000
CY2022Q4	emma	Deferred Tax Liabilities Unrealized Loss On Trading Securities DeferredTaxLiabilitiesUnrealizedLossOnTradingSecurities	426000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	427000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	427000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1200000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4000000
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	12100000
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	11800000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-851000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2242000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-173000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-453000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1224000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3964000
CY2023	emma	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	73000
CY2022	emma	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-384000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	285000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	450000
CY2023	emma	Effective Income Tax Rate Reconciliation Other Comprehensive Income Tax Benefit EffectiveIncomeTaxRateReconciliationOtherComprehensiveIncomeTaxBenefit	-100000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2501000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-375000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-59000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	60000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1138000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1171000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	856000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3165000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	461000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2704000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2300000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2800000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2700000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3300000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.129
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.129
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	78000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	74000

Files In Submission

Name	View Source	Status
0000950170-24-080918-index-headers.html	Edgar Link	pending
0000950170-24-080918-index.html	Edgar Link	pending
0000950170-24-080918.txt	Edgar Link	pending
0000950170-24-080918-xbrl.zip	Edgar Link	pending
emma-20231231.htm	Edgar Link	pending
emma-20231231.xsd	Edgar Link	pending
emma-ex10_20.htm	Edgar Link	pending
emma-ex10_23.htm	Edgar Link	pending
emma-ex10_41.htm	Edgar Link	pending
emma-ex21_1.htm	Edgar Link	pending
emma-ex23_1.htm	Edgar Link	pending
emma-ex31_1.htm	Edgar Link	pending
emma-ex31_2.htm	Edgar Link	pending
emma-ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img49175599_0.jpg	Edgar Link	pending
img49175599_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
emma-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMMA
Emmaus Life Sciences, Inc. Stock $emma

2024 Q1 Form 10-K Financial Statement

#000095017024080918 Filed on July 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA Emmaus Life Sciences, Inc. Stock $emma

2024 Q1 Form 10-K Financial Statement

#000095017024080918 Filed on July 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA
Emmaus Life Sciences, Inc. Stock $emma